Clinical Trials Browser

Breast Carcinoma In Situ × Specimen Handling × 1 year × Clear all

NCT06184750 2026-03-19

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Phase 2 Recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT05941520 2026-03-18

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Phase 2 Recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT02954874 2026-03-17

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Phase 3 Active not recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05755269 2026-01-28

Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT04959474 2026-01-23

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

Phase NA Recruiting

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Triple Negative Breast Neoplasms

NCT06538389 2025-08-29

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

Phase 2 Recruiting

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT07044310 2025-07-29

5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss

Phase 2 Recruiting

Breast Carcinoma In Situ